The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Open accessAbstract
Glioblastomas belong to the most aggressive human cancers with short survival times. Due to the blood‐brain barrier, they are mostly inaccessible to traditional chemotherapy. We have recently shown that doxorubicin bound to polysorbate‐coated nanoparticles crossed the intact blood‐brain barrier, thus reaching therapeutic concentrations in the brain. Here, we investigated the therapeutic potential of this formulation of doxorubicin in vivo using an animal model created by implantation of 101/8 glioblastoma tumor in rat brains. Groups of 5–8 glioblastoma‐bearing rats (total n = 151) were subjected to 3 cycles of 1.5–2.5 mg/kg body weight of doxorubicin in different formulations, including doxorubicin bound to polysorbate‐coated nanoparticles. The animals were analyzed for survival (% median increase of survival time, Kaplan‐Meier). Preliminary histology including immunocytochemistry (glial fibrillary acidic protein, ezrin, proliferation and apoptosis) was also performed. Rats treated with doxorubicin bound to polysorbate‐coated nanoparticles had significantly higher survival times compared with all other groups. Over 20% of the animals in this group showed a long‐term remission. Preliminary histology confirmed lower tumor sizes and lower values for proliferation and apoptosis in this group. All groups of animals treated with polysorbate‐containing formulations also had a slight inflammatory reaction to the tumor. There was no indication of neurotoxicity. Additionally, binding to nanoparticles may reduce the systemic toxicity of doxorubicin. This study showed that therapy with doxorubicin bound to nanoparticles offers a therapeutic potential for the treatment of human glioblastoma. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
The Statistical Analysis of Failure Time Data
Young, W. R. (1981) · Journal of Quality Technology · doi:10.1080/00224065.1981.11978770 · Cited by 1,666
DeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,663
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Self-citationPassage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Ivanov, A. A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 539
Self-citationSignificant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
Self-citationKreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
Self-citationAlyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352
Self-citation
Cited by
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Nanotechnology-based drug delivery systems
Suri, S. S., Fenniri, H., & Singh, B. (2007) · Journal of Occupational Medicine and Toxicology · doi:10.1186/1745-6673-2-16 · Cited by 755
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Nanotechnology for the biologist
McNeil, S. E. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205074 · Cited by 613
Lipid nanocapsules: A new platform for nanomedicine
Huynh, N. T., Passirani, C., Saulnier, P., & Benoit, J. P. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.026 · Cited by 595
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Self-citationInteraction of Nanoparticles with Cells
Mailänder, V., & Landfester, K. (2009) · Biomacromolecules · doi:10.1021/bm900266r · Cited by 576
Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes
Rudramurthy, G., Swamy, M., Sinniah, U., & Ghasemzadeh, A. (2016) · Molecules · doi:10.3390/molecules21070836 · Cited by 556
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Self-citationBlood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Nanoparticles—a historical perspective
KREUTER, J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.021 · Cited by 540
Self-citationSolid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
Drug transport to brain with targeted nanoparticles
Olivier, J.-C. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.108 · Cited by 444
Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
Self-citationPolymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860701794353 · Cited by 427
Active targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer
Kawasaki, E. S., & Player, A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.03.002 · Cited by 368
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Electrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in Vitro
Xie, J., & Wang, C.-H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9036-z · Cited by 339
Brain cancer diagnosis and therapy with nanoplatforms☆
KOO, Y., REDDY, G., BHOJANI, M., SCHNEIDER, R., PHILBERT, M., REHEMTULLA, A., ROSS, B., & KOPELMAN, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.012 · Cited by 326
Colloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain?
Garcia-Garcia, E., Andrieux, K., Gil, S., & Couvreur, P. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.031 · Cited by 314
Juillerat-Jeanneret, L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.005 · Cited by 314
Kim, D., Lee, E. S., Oh, K. T., Gao, Z. G., & Bae, Y. H. (2008) · Small · doi:10.1002/smll.200701275 · Cited by 313
Michaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097139 · Cited by 303
Self-citationWong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S. Z., & Wu, X. Y. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0282-x · Cited by 303
Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Müller, R., Uhl, R., Kreuter, J., & Gelperina, S. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.015 · Cited by 298
Self-citationGelperina, S., Maksimenko, O., Khalansky, A., Vanchugova, L., Shipulo, E., Abbasova, K., Berdiev, R., Wohlfart, S., Chepurnova, N., & Kreuter, J. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.09.003 · Cited by 293
Self-citationInorganic nanoparticles engineered to attack bacteria
Miller, K. P., Wang, L., Benicewicz, B. C., & Decho, A. W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00041f · Cited by 290
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Kreuter, J., & Langer, K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.036 · Cited by 275
Self-citationJain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6966-1 · Cited by 264
Nance, E., Zhang, C., Shih, T.-Y., Xu, Q., Schuster, B. S., & Hanes, J. (2014) · ACS Nano · doi:10.1021/nn504210g · Cited by 262
Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S., & Langer, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.12.012 · Cited by 262
Self-citationAryal, M., Vykhodtseva, N., Zhang, Y.-Z., Park, J., & McDannold, N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.007 · Cited by 261
Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)
Ulbrich, K., Knobloch, T., & Kreuter, J. (2011) · Journal of Drug Targeting · doi:10.3109/10611861003734001 · Cited by 259
Self-citationWagner, S., Zensi, A., Wien, S. L., Tschickardt, S. E., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032568 · Cited by 257
Self-citationBrain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221
Self-citationNanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (bbb).
Kreuter, J. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2012.692491 · Cited by 172
Self-citationAmbruosi, A., Khalansky, A. S., Yamamoto, H., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600636135 · Cited by 119
Self-citationTherapeutics, imaging and toxicity of nanomaterials in the central nervous system.
Nunes, A., Al-Jamal, K. T., & Kostarelos, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.026 · Cited by 75
Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
Grabrucker, A. M., Chhabra, R., Belletti, D., Forni, F., Vandelli, M. A., Ruozi, B., & Tosi, G. (2013) · Topics in Medicinal Chemistry · doi:10.1007/7355_2013_22 · Cited by 53
Metadata
- Authors
- Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., & Gelperina, S. E.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-01-22
- Volume
- 109
- Issue
- 5
- Pages
- 759-767
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2005542583
- Cited by
- 434
- References
- 43
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.